ATE314063T1 - Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung - Google Patents

Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung

Info

Publication number
ATE314063T1
ATE314063T1 AT02777129T AT02777129T ATE314063T1 AT E314063 T1 ATE314063 T1 AT E314063T1 AT 02777129 T AT02777129 T AT 02777129T AT 02777129 T AT02777129 T AT 02777129T AT E314063 T1 ATE314063 T1 AT E314063T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
combination
radiation
head
Prior art date
Application number
AT02777129T
Other languages
German (de)
English (en)
Inventor
Bernd Groner
Thorsten Heinzel
Bernd Hentsch
Winfried Stephan Wels
Peter A Herrlich
Saverio Minucci
Pier Giuseppe Pelicci
Martin Goettlicher
Original Assignee
G2M Cancer Drugs Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2M Cancer Drugs Ag filed Critical G2M Cancer Drugs Ag
Application granted granted Critical
Publication of ATE314063T1 publication Critical patent/ATE314063T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02777129T 2001-09-18 2002-09-17 Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung ATE314063T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01121722A EP1293205A1 (en) 2001-09-18 2001-09-18 Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
PCT/EP2002/010419 WO2003024442A2 (en) 2001-09-18 2002-09-17 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease

Publications (1)

Publication Number Publication Date
ATE314063T1 true ATE314063T1 (de) 2006-01-15

Family

ID=8178602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777129T ATE314063T1 (de) 2001-09-18 2002-09-17 Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung

Country Status (11)

Country Link
US (1) US20050038113A1 (https=)
EP (4) EP1293205A1 (https=)
JP (1) JP2005512961A (https=)
AT (1) ATE314063T1 (https=)
AU (1) AU2002338716B2 (https=)
CA (1) CA2460713A1 (https=)
CY (1) CY1105552T1 (https=)
DE (1) DE60208397T2 (https=)
DK (1) DK1427403T3 (https=)
ES (1) ES2252519T3 (https=)
WO (1) WO2003024442A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
CN102349927A (zh) * 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP5156392B2 (ja) * 2005-02-03 2013-03-06 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤を用いる併用療法
US7869590B2 (en) * 2005-04-12 2011-01-11 Broadcom Corporation Method and system for hardware accelerator for implementing f9 integrity algorithm in WCDMA compliant handsets
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US9186339B2 (en) * 2005-11-16 2015-11-17 Universidad Nacional Autonoma De Mexico Use of transcriptome modifying agents and chemotherapy or radiotherapy against cancer
RU2389484C2 (ru) * 2005-11-18 2010-05-20 Универсидад Насиональ Аутонома Де Мексико Применение модифицирующих транскриптом агентов и химиотерапии или радиотерапии против рака
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP5113038B2 (ja) * 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
DE102006022877B4 (de) * 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California Small molecule potentiator of hormonal therapy for breast cancer
CA2671649A1 (en) * 2006-12-06 2008-06-12 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
WO2010064422A1 (ja) * 2008-12-02 2010-06-10 静岡県公立大学法人 ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
KR101733189B1 (ko) * 2010-10-06 2017-05-08 (주)아모레퍼시픽 손톱 또는 발톱 성장 촉진용 조성물
CA2829263C (en) * 2011-03-21 2020-05-12 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
JP6551963B2 (ja) * 2014-05-14 2019-07-31 国立大学法人京都大学 巨核球前駆細胞の製造方法
MX388409B (es) 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
CN117693363A (zh) * 2021-07-27 2024-03-12 东丽株式会社 用于癌的治疗和/或预防的药品

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
CA1339034C (en) * 1988-08-22 1997-04-01 Paul A. Tremblay Platinum complexes of single isomer neoalkyl acids
JPH0279969A (ja) * 1988-09-19 1990-03-20 Shigeyoshi Fujimoto 細胞障害性ｔ細胞誘導及び活性化の方法
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0632008B1 (en) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentanoic acid derivatives
US5672746A (en) * 1994-08-30 1997-09-30 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
AU2337601A (en) * 1999-12-23 2001-07-09 Ontario Cancer Institute, The Inhibition of gsk-3beta
EP1170008A1 (en) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors

Also Published As

Publication number Publication date
WO2003024442A2 (en) 2003-03-27
EP1602371A2 (en) 2005-12-07
DK1427403T3 (da) 2006-04-03
WO2003024442A3 (en) 2003-09-18
EP1602371A3 (en) 2006-11-15
EP1427403B1 (en) 2005-12-28
CY1105552T1 (el) 2010-07-28
AU2002338716B2 (en) 2007-08-16
DE60208397D1 (de) 2006-02-02
DE60208397T2 (de) 2006-07-13
EP1427403A2 (en) 2004-06-16
EP1293205A1 (en) 2003-03-19
JP2005512961A (ja) 2005-05-12
ES2252519T3 (es) 2006-05-16
CA2460713A1 (en) 2003-03-27
EP1529527A3 (en) 2005-05-25
EP1427403B8 (en) 2006-03-22
EP1529527A2 (en) 2005-05-11
US20050038113A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DE60208397D1 (de) Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung
ATE482227T1 (de) Modulatoren pharmakologischer mittel
DE50310516D1 (de) Fredericamycin-derivate
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
DE60229767D1 (de) Verwendung von laminarin in der behandlung von krebs
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
YU73301A (sh) eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
NZ515388A (en) Polynucleotides and polypeptides used to stimulate leukocyte growth and to modulate angiogenesis and treat neurological conditions
DE60330914D1 (de) Arzneimittel mit shikonin als wirkstoff
KR102464528B1 (ko) 웨어러블 광 조사기
ATE409039T1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
RU2015127037A (ru) Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
ATE290909T1 (de) Anti-ischemischer wirkstoff
IL153586A0 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
RU2007119229A (ru) Способ фотодинамической терапии опухолей
Bychkovsky et al. Drugs based on modified polysaccharides for the local chemotherapy of malignant tumors
GR1004951B (el) Στοματοδιασπειρωμενα δισκια φλουοξετινης ΄η και αλατων αυτης
GR20030100526A (el) Αναβραζοντα δισκια φλουοξετινης η και αλατων αυτης

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1427403

Country of ref document: EP